Shots:

• Cadalimab will be available in 40mg/0.8ml as a pre-filled syringe and is targeted for the reduction in signs and symptoms of Rheumatoid Arthritis- Juvenile Idiopathic Arthritis- Ankylosing Spondylitis- Psoriatic Arthritis- and Psoriasis
• Additionally- Cadila has launched 3 more biosimilar products Bevaro- Ritucad- and NuPTH in the last 2 months
• Adalimumab is a mAb and a disease-modifying antirheumatic drug that works by inactivating tumor necrosis factor-alpha (TNFα) recommended in the treatment of many diseases. In Feb 2020- Cadila concluded and cleared USFDA inspection

Ref: Cadila | Image: Signbox